Imperial College London
Alternate

DrRebeccaBaggaley

Faculty of Medicine, School of Public Health

Honorary Research Fellow
 
 
 
//

Contact

 

r.baggaley Website

 
 
//

Location

 

Praed StreetSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Baggaley:2017:10.1016/S2352-3018(17)30123-6,
author = {Baggaley, RF and Irvine, MA and Leber, W and Cambiano, V and Figueroa, J and McMullen, H and Anderson, J and Santos, AC and Terris-Prestholt, F and Miners, A and Hollingsworth, TD and Griffiths, CJ},
doi = {10.1016/S2352-3018(17)30123-6},
journal = {Lancet HIV},
pages = {E465--E474},
title = {Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis},
url = {http://dx.doi.org/10.1016/S2352-3018(17)30123-6},
volume = {4},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundEarly HIV diagnosis reduces morbidity, mortality, the probability of onward transmission, and their associated costs, but might increase cost because of earlier initiation of antiretroviral treatment (ART). We investigated this trade-off by estimating the cost-effectiveness of HIV screening in primary care.MethodsWe modelled the effect of the four-times higher diagnosis rate observed in the intervention arm of the RHIVA2 randomised controlled trial done in Hackney, London (UK), a borough with high HIV prevalence (≥0·2% adult prevalence). We constructed a dynamic, compartmental model representing incidence of infection and the effect of screening for HIV in general practices in Hackney. We assessed cost-effectiveness of the RHIVA2 trial by fitting model diagnosis rates to the trial data, parameterising with epidemiological and behavioural data from the literature when required, using trial testing costs and projecting future costs of treatment.FindingsOver a 40 year time horizon, incremental cost-effectiveness ratios were £22201 (95% credible interval 12662–132452) per quality-adjusted life-year (QALY) gained, £372207 (268162–1903385) per death averted, and £628874 (434902–4740724) per HIV transmission averted. Under this model scenario, with UK cost data, RHIVA2 would reach the upper National Institute for Health and Care Excellence cost-effectiveness threshold (about £30000 per QALY gained) after 33 years. Scenarios using cost data from Canada (which indicate prolonged and even higher health-care costs for patients diagnosed late) suggest this threshold could be reached in as little as 13 years.InterpretationScreening for HIV in primary care has important public health benefits as well as clinical benefits. We predict it to be cost-effective in the UK in the medium term. However, this intervention might be cost-effective far sooner, and even cost-saving, in settings where long-term health-car
AU  - Baggaley,RF
AU  - Irvine,MA
AU  - Leber,W
AU  - Cambiano,V
AU  - Figueroa,J
AU  - McMullen,H
AU  - Anderson,J
AU  - Santos,AC
AU  - Terris-Prestholt,F
AU  - Miners,A
AU  - Hollingsworth,TD
AU  - Griffiths,CJ
DO  - 10.1016/S2352-3018(17)30123-6
EP  - 474
PY  - 2017///
SN  - 2405-4704
SP  - 465
TI  - Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis
T2  - Lancet HIV
UR  - http://dx.doi.org/10.1016/S2352-3018(17)30123-6
UR  - http://hdl.handle.net/10044/1/56183
VL  - 4
ER  -
Download